HYLATOPICPLUS CREAM Rx
Generic Name and Formulations:
Water, glycerin, ethylhexyl palmitate, cetearyl alcohol, propylene glycol, dicetyl phosphate, petrolatum, theobroma grandiflorum seed butter, dimethicone, ceteareth-10 phosphate, steareth-10, phenoxyethanol, hydroxypropyl bispalmitamide MEA (ceramide), tocopheryl acetate, sodium hyaluronate, disodium EDTA and sodium hydroxide; crm.
Encore Dermatology, Inc.
Indications for HYLATOPICPLUS CREAM:
Dermatitis (including radiation dermatitis). Dry skin.
Adults and Children:
Apply and massage into affected area 3 times daily or as needed. Broken skin: may be occluded.
Avoid eyes and exposure to sun. Treatment may be continued during antiinfective therapy. Reevaluate if no improvement after 10–14 days.
Radiation therapy: may dissolve fuchsin dye; do not use 4 hours prior to session.
Foam—100g, 150g; Crm—100g, 450g, Lotion—14oz
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners